p. 241−250
2090-2549
Vol.48/No.2
p. 251−258
2090-2549
Vol.48/No.2
p. 259−268
2090-2549
Vol.48/No.2
p. 269−274
2090-2549
Vol.48/No.2
p. 275−288
2090-2549
Vol.48/No.2
p. 289−299
2090-2549
Vol.48/No.2
p. 301−308
2090-2549
Vol.48/No.2
p. 309−326
2090-2549
Vol.48/No.2
p. 327−334
2090-2549
Vol.48/No.2
p. 335−342
2090-2549
Vol.48/No.2
p. 343−355
2090-2549
Vol.48/No.2
p. 357−362
2090-2549
Vol.48/No.2
p. 363−368
2090-2549
Vol.48/No.2
p. 369−378
2090-2549
Vol.48/No.2
0.05) during S and G2-M phases in case of HepG2 cells, while it was significantly elevated during G2-M phase in case of MCF-7 treatment. Treated cell lines showed a significant apoptotic % during the Pre-G1 phase (P<0.05). ER and HER-2 as specific markers for MCF-7 and BCL-2 in treated HEPG-2 cells were significantly down regulated (P<0.05), while, p53was significantly up regulated (P<0.05).]]>
p. 379−388
2090-2549
Vol.48/No.2
p. 389−398
2090-2549
Vol.48/No.2
p. 399−404
2090-2549
Vol.48/No.2
p. 405−416
2090-2549
Vol.48/No.2
p. 417−424
2090-2549
Vol.48/No.2
p. 425−431
2090-2549
Vol.48/No.2
p. 433−442
2090-2549
Vol.48/No.2
p. 443−448
2090-2549
Vol.48/No.2
p. 449−458
2090-2549
Vol.48/No.2
p. 459−464
2090-2549
Vol.48/No.2
p. 465−474
2090-2549
Vol.48/No.2
p. 475−480
2090-2549
Vol.48/No.2
p. 281−281
2090-2549
Vol.48/No.2
p. 55−66
2090-2549
Vol.48/No.2